HeraMED and Wingwomen collaboration for Cardio Care initiative

HeraMED Limited (ASX:$HMD) has signed an agreement with Wingwomen, a virtual and in-person Femhealth startup, to undertake a 90-day evaluation for a Cardio Care initiative scheduled to begin in January 2024. The initiative aims to support pregnant women in their third and fourth trimesters, focusing on evaluating the use of HeraCARE technology for hypertensive pregnancy conditions.

Executive Commentary on Collaboration and Initiative

HeraMED President North America, Keith Koby, expressed excitement about the collaboration with Wingwomen, highlighting the potential of the evaluation to demonstrate HeraCARE's ability to improve maternity care. He emphasized the importance of addressing the challenges faced by women, particularly those lacking access to care and women of color in the USA. Wingwomen Founder and CEO, Adonica Shaw, shared her personal experience as a Preeclampsia Survivor, underscoring the potential of the collaboration to improve outcomes for families in need of lifesaving solutions.

Summary of HeraMED and Wingwomen Collaboration

HeraMED Limited (ASX:HMD) has partnered with Wingwomen to evaluate the use of HeraCARE technology for hypertensive pregnancy conditions. The collaboration aims to support pregnant women in their third and fourth trimesters, with a focus on improving maternity care and addressing the challenges faced by women, particularly those lacking access to care and women of color in the USA. The evaluation is expected to provide valuable data for the commercialization of HeraCARE in the USA, potentially leading to a phased deployment of the technology to clinics and hospitals facing maternity crises. The initiative is set to launch in January 2024, with results expected in the second half of 2024, paving the way for a potential commercial agreement between HeraMED and Wingwomen.